
Champions Oncology CSBR
$ 7.7
14.58%
Quarterly report 2025-Q2
added 09-15-2025
Champions Oncology Operating Cycle 2011-2025 | CSBR
Annual Operating Cycle Champions Oncology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.5 | 63.8 | 59.4 | 61.3 | 52.3 | 52 | 59 | 70.6 | 53.9 | 42.8 | 43.7 | 41.9 | 21.9 | 29.8 | 58.4 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 70.6 | 21.9 | 51.8 |
Quarterly Operating Cycle Champions Oncology
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 67.4 | - | 66 | 60.2 | - | 65.7 | 61.6 | - | 62.5 | 58.5 | 62.6 | 52.6 | 49.5 | 2.62 K | -3.9 K | - | 52.9 | 49.6 | 44.2 | 41.5 | 55.6 | 46.7 | 56 | - | 68.6 | 57.8 | 56.3 | 43.6 | - | 46 | 44.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.89 K | - | - | - | - | 4.15 K | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.15 K | -3.9 K | 260 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.93 | 4.78 % | $ 818 M | ||
|
Aclaris Therapeutics
ACRS
|
6.01 | $ 3.2 | -1.69 % | $ 247 M | ||
|
Aptevo Therapeutics
APVO
|
191 | $ 1.07 | -5.75 % | $ 295 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | ||
|
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
195 | $ 26.45 | 4.67 % | $ 1.28 B | ||
|
Anika Therapeutics
ANIK
|
325 | $ 9.6 | 0.37 % | $ 141 M | ||
|
Catalyst Biosciences
CBIO
|
410 | $ 12.98 | -7.91 % | $ 854 M | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
Axon Enterprise
AXON
|
116 | $ 548.58 | -2.78 % | $ 41.6 B | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
360 | $ 2.37 | 2.83 % | $ 14.9 M | ||
|
AstraZeneca PLC
AZN
|
206 | $ 91.59 | 1.95 % | $ 96.9 B | ||
|
Celldex Therapeutics
CLDX
|
86.5 | $ 27.09 | -1.53 % | $ 1.74 M | ||
|
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
408 | $ 11.33 | -1.78 % | $ 733 M | ||
|
Biogen
BIIB
|
452 | $ 175.2 | 0.63 % | $ 25.5 B | ||
|
Abeona Therapeutics
ABEO
|
387 | $ 5.07 | -5.5 % | $ 108 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
364 | $ 87.67 | -0.36 % | $ 9.05 B | ||
|
ADiTx Therapeutics
ADTX
|
841 | $ 1.43 | -36.18 % | $ 18.8 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
349 | - | -7.31 % | $ 87 M | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
137 | $ 24.29 | 2.84 % | $ 2.88 B |